Sufentanil - Orexo

Drug Profile

Sufentanil - Orexo

Alternative Names: OX27

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Orexo
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer-pain in Sweden (Sublingual, Tablet)
  • 17 Feb 2014 Biomarkers information updated
  • 21 Dec 2011 Orexo completes a pharmacokinetic study of OX 27 in healthy volunteers in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top